India's First: Curapod wearable gets Class II nod for drug-free musculoskeletal pain relief

India's First: Curapod wearable gets Class II nod for drug-free musculoskeletal pain relief

By: IPP Bureau

Last updated : December 24, 2025 6:50 pm



Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries


CURAPOD, a Made-in-India health-tech brand backed by Litemed, brings a clinically validated wearable designed for effective, everyday pain relief. Registered with the Central Drugs Standard Control Organization (CDSCO) and the FDA, it stands as India’s first non-invasive personalised pain management device.

Designed for over 30 conditions, including chronic back and knee pain, arthritis, tendonitis, sports injuries, and everyday strain, the device is already being adopted by physiotherapy centres, wellness hubs, and early consumers seeking trusted, drug-free relief.  

The device uses medical-grade photobiomodulation technology to deliver red and near-infrared light that promotes cellular repair, reduces inflammation, and accelerates recovery. Its adaptive engine calibrates therapy intensity in real time based on muscle response, often providing noticeable relief within 30 minutes.

The companion mobile app personalises therapy plans, tracks progress, and monitors pain, enabling professional-grade treatment in the comfort of home. CURAPOD provides 100% drug-free therapy with no side effects and comes with a 1-year warranty along with free expert consultation.  

“CURAPOD’s adaptive system adjusts intensity based on user comfort, offering consistent and targeted pain relief,” said Surya Maguluri, Founder & Chief Technology Officer, CURAPOD, backed by Litemed India Private Limited. “This data-driven approach allows clinicians to monitor progress remotely, refine therapy programs, and deliver measurable outcomes, making it the first wearable in India to integrate clinical precision with everyday usability.”  

The device is currently available PAN India through their D2C website and will be listed on leading marketplaces from the first quarter of 2026, with broader retail and e-commerce expansion planned over the following two years.  

“From operations to delivery, we focused on building trust, accessibility, and reliability,” said Sri Velliyur, Co-Founder & CEO, CURAPOD, backed by Litemed India Private Limited.

“By manufacturing entirely in India and partnering with wellness chains and physiotherapy networks, we ensure the device reaches users consistently and efficiently, including in tier-2 & 3 cities. Our goal is to make clinically validated, non-invasive pain relief widely accessible without compromising quality or affordability.”

CURAPOD Litemed Central Drugs Standard Control Organization FDA knee pain arthritis tendonitis sports injuries Sri Velliyur

First Published : December 24, 2025 12:00 am